Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) shares were up 10.2% on Monday . The stock traded as high as $16.99 and last traded at $16.98. Approximately 125,846 shares were traded during trading, a decline of 31% from the average daily volume of 183,550 shares. The stock had previously closed at $15.41.
Analysts Set New Price Targets
A number of research firms have issued reports on ZBIO. Wedbush reaffirmed an "outperform" rating and issued a $35.00 price target on shares of Zenas BioPharma in a research report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Zenas BioPharma in a report on Friday, May 16th.
View Our Latest Analysis on Zenas BioPharma
Zenas BioPharma Stock Performance
The company has a market cap of $600.26 million and a PE ratio of -4.04. The stock's fifty day simple moving average is $12.01.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The business had revenue of $10.00 million during the quarter, compared to analysts' expectations of $5.00 million.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. Jefferies Financial Group Inc. bought a new stake in shares of Zenas BioPharma during the first quarter valued at approximately $348,000. Nuveen LLC bought a new stake in Zenas BioPharma during the 1st quarter valued at $250,000. Geode Capital Management LLC raised its stake in Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company's stock valued at $3,621,000 after acquiring an additional 16,461 shares in the last quarter. New York State Common Retirement Fund acquired a new position in Zenas BioPharma during the 1st quarter worth $49,000. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock valued at $89,000 after purchasing an additional 2,679 shares during the period.
Zenas BioPharma Company Profile
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
See Also
Before you consider Zenas BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas BioPharma wasn't on the list.
While Zenas BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access